Alterations in the tumor microenvironment, including the increased presence of immunosuppressive cells, such as regulatory T cells (Tregs) or myeloid-derived suppressor cells (MDSCs), can establish an immunosuppressive environment that dampens the effectiveness of anti-PD1 therapy. Here, PDCD1 is linked to neoplasm.